Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilavonemab in Early Alzheimer's Disease
NCT02880956Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2017
- Primary completion
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of tilavonemab in Alzheimer's disease (AD), sponsored by AbbVie Inc.. Started Jan 2017; status: completed.
02
Drugs
tilavonemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02880956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02880956.